ArticleDermatology practical & conceptual2026
Comparative Efficacy of Topical N-Acetylcysteine-Doxycycline versus Benzoyl Peroxide-Doxycycline in Moderate Acne Vulgaris: An Add-on Double-Blind Randomized Controlled Trial.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcne vulgaris is a prevalent skin disorder, especially among adolescents. While topical retinoid and benzoyl peroxide (BPO) are standard treatments, their side effects often decrease patient adherence.
objectivesThis study aimed to explore the efficacy and safety of topical N-acetylcysteine (NAC) plus doxycycline compared to BPO-doxycycline in moderate acne vulgaris.
methodIn this double-blind randomized clinical trial, 40 patients were allocated into one of two groups: Group A received 100 mg/day doxycycline+5% NAC, while Group B received 100 mg/day doxycycline +5% BPO. Patients were assessed over three months using total lesion count (TLC), Investigator Global Assessment (IGA), Global Acne Grading System (GAGS), and Cardiff Acne Disability Index (CADI). Statistical analysis was performed using STATA 14.2, with P<0.05 considered significant.
resultsIn comparison with BPO, NAC treatment led to a significantly greater improvement in CADI scores (MD=-3.60, 95% CI: -4.26 - -2.95, P<0.001), GAGS scores (MD = -9.76, 95% CI: -11.84 - -7.68, P<0.001), TLC (MD = -4.29, 95% CI: -6.38 - -2.19, P=0.002), inflammatory lesion count (MD = -2.93, 95% CI: -5.18 - -0.68, P=0.003), and IGA scores (MD = -0.85, 95% CI: -1.12 - -0.58, P<0.001). Repeated mixed measures ANOVA further confirmed significant between-group differences in GAGS scores at the second and third months of patients' follow-up. Only one patient reported mild scaling with receiving NAC.
conclusionTopical NAC combined with doxycycline was significantly more effective than BPO-doxycycline in acne treatment, with minimal adverse effects. These results indicate that NAC may serve as an acceptable alternative for the treatment of moderate acne vulgaris.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.